A term sheet is a short, mostly nonbinding outline of a priced investment. The lead investor uses it to put valuation, the size of the check, the option pool, liquidation preference, pro rata rights, board seats and other control terms on one or two pages before anyone drafts the full legal documents. Carta’s fundraising guide, updated October 7, 2026, describes it as a preliminary framework for a priced round, most often at Series A and later, though a seed round can use one too.
You’ll also hear offering terms, a Series A term sheet or, loosely, “the deal memo.” Signing it is not the same as closing the round. A few clauses, usually confidentiality, a no-shop (exclusivity) window and a promise to negotiate in good faith, can be binding from the moment you sign. This is education, not legal advice. Have a startup attorney read the document before you agree to it.
What is, and is not, binding
Carta’s guide is clear on the split, and it matches what most counsel will tell you. The economic and control terms are a negotiated outline. Either side can generally walk away before the definitive agreements are signed, which is the point of starting with a short document instead of a 100-page set of contracts.
The binding pieces are the ones that restrict your behavior while you talk. A no-shop clause, for a defined window, says you will not solicit or negotiate competing offers. Confidentiality says you will not publish the terms or the diligence you exchange. Good-faith negotiation says you will actually work toward closing, not use the paper as a prop. The length of the no-shop is one of the terms Carta lists as commonly negotiated. Do not sign a long exclusivity period just to “keep the process moving.”
Valuation, the check size and the option pool
Pre-money valuation is what the company is worth, for this deal, before the new money goes in. Post-money valuation is pre-money plus the new investment. If an investor puts in $10 million at a $40 million pre-money valuation, the post-money valuation is $50 million, and that check is 20% of the company on a post-money basis, before you layer in other adjustments.
The option pool is one of those adjustments, and it is often where a clean-looking valuation gets less clean. The term sheet reserves a block of shares for future hires. Investors often want that pool created or topped up on a pre-money basis, which means existing holders, usually the founders, absorb the dilution before the new money is counted. The same headline pre-money number with a larger pre-money pool is a worse deal for the people already on the cap table. Carta’s guide flags pool size, and whether it is carved out pre- or post-money, as a term founders commonly negotiate, and Carta data there suggests founders can start a pool at 8% to 10% of equity and expand it later rather than taking all of that dilution up front.
A priced round also changes how you grant options going forward. The preferred price is not automatically the fair market value of the common stock. That is why companies get a 409A valuation after a financing, so new grants are priced against an independent appraisal of the common, not against the preferred issue price. And the pool on the term sheet only helps you if you actually grant those options under the right type of award, which is a separate decision we already cover in ISO vs NSO.
Liquidation preference, with a worked example
Preferred stock gets paid before common in a sale, a winding up, or a “deemed liquidation” such as a merger, unless the preferred holders elect otherwise. The NVCA model documents, which are the industry’s standard starting templates, offer more than one way to write that preference. Carta’s October 2026 guide treats a 1x non-participating liquidation preference as a usual standard term, with participating versus non-participating as something founders still negotiate.
Non-participating means the investor chooses the better of two paths: take the preference (typically their money back, or a multiple of it), or convert to common and take their ownership percentage of the proceeds. They do not get both. Participating preferred takes the preference first, then also shares in what is left, as if they had converted. That second bite is why founders push back on it.
Here is a labeled teaching example, not a real deal. An investor puts in $5 million at a $15 million pre-money valuation. The post-money valuation is $20 million, and the new preferred owns 25%.
If the company later sells for $8 million and the preferred is 1x non-participating, the investor takes the $5 million preference. Common splits the remaining $3 million.
If the company sells for $40 million, 25% as-converted is $10 million, which is better than the $5 million preference, so the investor takes the as-converted path.
If the company sells for $20 million and the preferred is 1x participating, the investor takes $5 million first, then 25% of the remaining $15 million, or $3.75 million, for $8.75 million in total. Under 1x non-participating, that same $20 million sale would have paid the investor $5 million (the preference and the as-converted amount are the same). The extra $3.75 million is the cost of participation.
A 2x or 3x preference, or participating preferred with no cap, can wipe out common in a modest exit. Carta data cited in that October 2026 guide shows the down-round rate fell to 11.4% in the first quarter of 2026, from a peak of about 22% in 2023, and notes that liquidation preferences and participation rights were near multi-year lows. That is a dated snapshot, not a promise that an aggressive term will not show up in your deal.
Pro rata, anti-dilution and the control terms
Pro rata rights let a major investor buy enough shares in a later round to keep their ownership percentage. They live in the investor rights documents, and they are one of the terms Carta calls usually standard. They matter because a lead who can keep taking their share will still be on the cap table when you raise again, for better and for worse.
Anti-dilution protection adjusts the preferred’s conversion price if you later sell stock at a lower price. NVCA-style term sheets typically offer a weighted-average adjustment, which spreads the hit across the new shares issued, or a full ratchet, which resets the conversion price all the way down to the new lower price. The full ratchet is the aggressive version. I would not accept it without a clear reason and a lawyer in the room.
Control is the other half of the paper. The term sheet usually sets how many board seats the preferred can appoint, how many the common (often the founders) keep, and how an independent seat, if there is one, gets filled. Carta lists board composition and who controls the independent seat as commonly negotiated terms. Protective provisions are veto rights, not day-to-day management: selling the company, issuing senior stock, taking on large debt, changing the charter, and sometimes hiring or firing senior executives or expanding the option pool. Drag-along rights can require minority holders to vote in favor of a sale if a stated majority agrees. None of these should be skated past because the valuation looks good.
After you sign, the real documents start
Carta’s sequence is the right one to keep in your head. Signing starts due diligence, not a close. Investors will review the cap table, contracts, intellectual property, financials and the story you sold them. Then counsel drafts the definitive agreements, typically a stock purchase agreement, an amended charter, an investors’ rights agreement, a voting agreement and right-of-first-refusal or co-sale documents. The round is not done until those are signed and the money is wired.
The National Venture Capital Association publishes model versions of these documents, including a model term sheet, at no charge. They are a reference, not a substitute for counsel who will mark up the actual paper in front of you. If two term sheets show up, that leverage usually matters more than a clever rewrite of a single clause. If only one shows up, do not let speed replace a careful read of preference, the option pool and the board.
Frequently Asked Questions
What is a term sheet in a startup financing?
A term sheet is a short outline of a priced investment, covering valuation, the check size, the option pool, economic rights such as liquidation preference and pro rata, and control terms such as board seats. It is mostly nonbinding, except for clauses like confidentiality and a no-shop window.
Is a term sheet legally binding?
Most of it is not. Either side can generally walk away before the definitive agreements are signed. Confidentiality, exclusivity (a no-shop period) and a good-faith negotiation clause are often binding once you sign. Have a lawyer confirm which sections bind you.
What is a 1x non-participating liquidation preference?
It lets preferred holders take the better of their money back (1x) or their as-converted share of the sale proceeds, not both. Participating preferred takes the preference first and then also shares in what remains. The NVCA model documents include both alternatives.
How does the option pool affect a term sheet valuation?
If the pool is carved out of the pre-money, existing holders absorb that dilution before the new investment is counted, which makes the same headline valuation worse for founders. Carta’s October 2026 guide flags pool size and pre- versus post-money treatment as a commonly negotiated term.
When do startups use a term sheet?
Term sheets are typical in a priced equity round, most often at Series A and later. A seed round can use one, but earlier raises are often done on a SAFE or a convertible note, which do not set a firm valuation in the same way.
What happens after you sign a term sheet?
Due diligence begins, then counsel drafts the definitive agreements. The financing is not closed until those documents are signed and the funds are wired. Treat the signature as the start of that work, not the finish line.
The post Term Sheet Explained: Valuation, Preference, Pro Rata and Board Seats appeared first on Addicted 2 Success.